Reason Evaluation of Initial Treatment Failure in Patients With CAP (RECAP)

Chinese Academy of Medical Sciences & Peking Union Medical College

Status: Unknown

Conditions: Community-acquired Pneumonia

Treatments: Drug: Moxifloxacin Hydrochloride and Sodium Chloride Injection

Study type: Observational

Funder types: Other

Identifiers

NCT03280004

HS-1279

Details and patient eligibility

About

This research is to evaluate the effect of different antibiotics (Moxifloxacin Hydrochloride and Sodium Chloride Injection vs. β-lactam antibiotics for injection +/- Azithromycin for Injection) on the early deterioration or progression (<72 h of treatment) of community acquired pneumonia and to study the effect of the early deterioration or progression on the prognosis of community acquired pneumonia.

Enrollment: 314 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age>=18y.
2. Diagnosed with CAP.
3. Need hospitalization.
4. Receive Moxifloxacin Hydrochloride and Sodium Chloride Injection or β-lactam antibiotics for injection +/- Azithromycin for Injection as initial treatment.
5. Signed informed consent form.

Exclusion criteria

Patients who meet any of the following criteria will not be included in the study:

1. Pneumonia is aquired more than 48h after admission or the patient was admitted to hospital within 30 days prior to admission.
2. Start antibiotic treatment before admission.
3. Gestational period or suckling period.
4. Admitted to ICU.
5. Immunocompromised patients.
6. Pneumonia is the terminal event of a serious disease.
7. Tuberculosis, lung cancer, non-infectious interstitial lung disease, pulmonary edema, atelectasis, pulmonary embolism, pulmanory eosinophilia, pulmonary vasculitis.
8. Allergic to the antibiotics of the study.

Trial design

314 participants in 2 patient groups

Moxifloxacin group

Treatment:

Drug: Moxifloxacin Hydrochloride and Sodium Chloride Injection

β-lactams group